Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
Sign in with Google. Opens in new tab
bullish
Moderna
Watchlist
Moderna Inc (MRNA US) - Insights About the Performance in Front of Omicron
Equity Bottom-Up
393 Views
04 Dec 2021 16:55
This article analyzed the revenue forecast of Moderna according to the various scenarios of Omicron depending on its severity. We also analyzed Moderna's vaccines when compared with peers' products.
SUMMARY
(Sign Up to Access)
Full Insight
(Paid Plans Only, 4-minute read)
Related Insights
More »
Loading
Trending Collections
More »
Index Rebalance
Japan
Philippines
Equity Bottom-Up
Event-Driven
India
Sell / Short Ideas
South Korea
Cross Asset Strategy
Asia ECM
Trending Insights
More »
SK Square: Time to Take Profits + Why Are There Holdco Discounts in the First Place?
Johns Lyng (JLG AU): PEP's A$4/Share Offer Looks Light
KOSPI Size Indices: Overlaps Between Active & Passive Flows
Ohayo Japan | Markets Climb as Nvidia, Bitcoin Soar
SBI Possible US$3bn QIP - Will Be One of the Largest Fund Raisings in India, Last One Didn’t Do Well
Top Unpaywalled Insights
More »
De-Dollarisation Debate : Unmasking USD Over-Valuation
US Equities Hit All-Time Highs—but Are Markets Ignoring Growing Risks?
Why America's Manufacturing Dreams Might Be Economic Nightmares
Systematic Global Macro: Data, AI, and Models Are Reshaping Investing | New Barbarians AI Agent #05
China Housing - A Mid-Year Check
Discussions
(Paid Plans Only)
Price Chart
(Sign Up to Access)
Insight Stream
Keymed Biosciences (2162.HK) - The Pipeline, the Concerns on Valuation Growth & The Trading Strategy
16 Dec 2021
Shanghai Junshi Bioscience (1877.HK) - Will Junshi Progress or Go Backwards Instead?
14 Dec 2021
Brii Biosciences (2137.HK) - With the Potential of “Zero to One”
08 Dec 2021
Moderna Inc (MRNA US) - Insights About the Performance in Front of Omicron
04 Dec 2021
2022 High Conviction (China Healthcare) - Seek the Relative Certainties Out of the Uncertainties
25 Nov 2021
Chongqing Zhifei Biological Products (300122.CH) 2021Q3 - Concerns Behind the High Growth
02 Nov 2021
CanSino Biologics (688185.CH/6185.HK) 2021/1H - Concerns on Key Products and the Outlook
07 Sep 2021
Top
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.53.10
x